2-Apr-2026
Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags
Seeking Alpha News (Wed, 1-Apr 12:15 PM ET)
TipRanks (Mon, 30-Mar 7:30 AM ET)
Business Wire (Mon, 16-Mar 4:30 PM ET)
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
Business Wire (Mon, 2-Mar 4:30 PM ET)
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
Business Wire (Mon, 2-Mar 4:15 PM ET)
IQVIA Releases its 2025 Sustainability Report
Business Wire (Fri, 27-Feb 4:47 PM ET)
IQVIA Expands End-to-End Drug Discovery Platform with Strategic Charles River Acquisition
Market Chameleon (Wed, 25-Feb 3:18 AM ET)
Business Wire (Wed, 25-Feb 7:00 AM ET)
Market Chameleon (Thu, 19-Feb 3:29 AM ET)
IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day
Business Wire (Wed, 18-Feb 4:15 PM ET)
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Iqvia Holdings trades on the NYSE stock market under the symbol IQV.
As of April 2, 2026, IQV stock price climbed to $173.26 with 732,281 million shares trading.
IQV has a beta of 1.09, meaning it tends to be more sensitive to market movements. IQV has a correlation of 0.16 to the broad based SPY ETF.
IQV has a market cap of $29.40 billion. This is considered a Large Cap stock.
Last quarter Iqvia Holdings reported $4 billion in Revenue and $3.42 earnings per share. This beat revenue expectation by $124 million and exceeded earnings estimates by $.13.
In the last 3 years, IQV traded as high as $261.73 and as low as $134.65.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
IQV has underperformed the market in the last year with a return of +1.2%, while the SPY ETF gained +18.2%. In the last 3 month period, IQV fell short of the market, returning -23.1%, while SPY returned -3.6%. However, in the most recent 2 weeks IQV has outperformed the stock market by returning +3.7%, while SPY returned -0.6%.
IQV support price is $167.77 and resistance is $177.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV shares will trade within this expected range on the day.